MDM2 and breast cancer: In this study, we examined the expression of p53 and MDM2 in BC CML cells, including proliferating and quiescent CD34+ CML progenitor cells, and assessed the effects of nutlin3a and its combination with the Bcl-2 inhibitor ABT-737 and the TKI nilotinib on the viability of these cells.